source
- Eli Lilly signs up to $1.9B deal with Ascidian Therapeutics for RNA editing in kidney diseaseAscidian Therapeutics recently presented early data indicating that its novel RNA‑editing approach to repair faulty genes appears safe in humans, focusing on kidney disease applications. Eli Lilly…
- NIH terminates $82 million outbreak research network, weakening pandemic preparednessIn 2020 the National Institutes of Health created a network of ten centers to expand knowledge on re‑emerging and emerging infectious diseases. The program was funded with $82 million over five yea…